There are two main categories of NHL: indolent and aggressive. According to the NCI, aggressive lymphomas do not typically return after successful treatment. However, indolent lymphomas often ...

Q4 2024 Management View CEO Ameet Mallik highlighted that 2024 was focused on execution, achieving key milestones, advancing ZYNLONTA, and strengthening the balance sheet. The company completed ...

The treatment aims to treat patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Indolent lymphomas are a rare type of lymphoma that tend to grow more slowly and have fewer ...

SUV remains the most widely used PET parameter to evaluate NHLs because it is directly associated with lymphoma aggressiveness.

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...

Dr. Gopal also conducts clinical research on low-toxicity drugs for patients with indolent lymphomas that activate the cancer cells’ self-destruct mechanism. Finally, Dr. Gopal studies new strategies ...

Expansion into indolent lymphomas, including follicular and marginal zone lymphomas, is projected to add $100 million to $200 million in peak revenue potential. ZYNLONTA net product revenues in Q4 ...